Interestingly, the potency of the novel NESs acquired by different AML-associated NPM mutants, as determined using an in vivo nuclear export assay, seems to inversely correlate to the severity of their folding defect [24]. The gene discussed is NPM1; the disease is acute myeloid leukemia.